Bosnia and Herzegovina vs Russia: Share of S. aureus infections resistant to methicillin
Bosnia and Herzegovina
26.5%
in 2022
Russia
17.0%
in 2021
Bosnia and Herzegovina rank
23rd
Russia rank
25th
Share of S. aureus infections resistant to methicillin over time
- Bosnia and Herzegovina
- Russia
How they compare
Bosnia and Herzegovina currently reports 26.5% against 17.0% in Russia, a difference of 9.5%.
That makes Bosnia and Herzegovina's figure about 1.6 times Russia's.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Bosnia and Herzegovina ahead.
Bosnia and Herzegovina ranks 23rd and Russia ranks 25th of 45 countries.
Russia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bosnia and Herzegovina | Russia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 17.6% | 19.1% | 1.5% | Russia |
| 2020s | 22.0% | 23.0% | 0.9% | Russia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of s. aureus infections resistant to methicillin, Bosnia and Herzegovina or Russia?
- Bosnia and Herzegovina, at 26.5% against 17.0% in Russia as of 2022.
- What is the difference in share of s. aureus infections resistant to methicillin between Bosnia and Herzegovina and Russia?
- 9.5%, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Russia?
- 5 years are reported by both, from 2017 to 2021.
- How do Bosnia and Herzegovina and Russia rank globally for share of s. aureus infections resistant to methicillin?
- Bosnia and Herzegovina ranks 23rd and Russia ranks 25th of 45 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of S. aureus infections resistant to methicillin. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%).